Care of patients with scleroderma in the intensive care setting

Journal of Intensive Care Medicine

Volumn 25, Issue 5, 2010, Pages 247-258

  Farber, Harrison W ^a   Simms, Robert W ^b   Lafyatis, Robert ^b  

^a BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Boston University Medical Campus   (United States)

Author keywords

complications; scleroderma; systemic sclerosis; treatment

Indexed keywords

AMLODIPINE; ANTINUCLEAR ANTIBODY; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BRAIN NATRIURETIC PEPTIDE; CAPTOPRIL; CENTROMERE ANTIBODY; CISAPRIDE; CORTICOSTEROID; CYCLIC GMP; CYCLOPHOSPHAMIDE; DIPEPTIDYL CARBOXYPEPTIDASE; DIURETIC AGENT; DOBUTAMINE; ENDOTHELIN RECEPTOR ANTAGONIST; ERYTHROMYCIN; ILOPROST; MILRINONE; NIFEDIPINE; OCTREOTIDE; OXYGEN; PHOSPHODIESTERASE INHIBITOR; PROSTACYCLIN; PROSTANOID; PROTON PUMP INHIBITOR; SCL 70 ANTIBODY; SILDENAFIL; UNIPROST; VASODILATOR AGENT;

CARDIOMYOPATHY; CARDIOPULMONARY HEMODYNAMICS; CARDIOVASCULAR DISEASE; CEREBROVASCULAR DISEASE; CHRONIC INFLAMMATION; CONGESTIVE HEART FAILURE; CONSTRICTIVE PERICARDITIS; CORONARY ARTERY DISEASE; CORONARY BLOOD VESSEL; DISEASE COURSE; DRUG MEGADOSE; ECHOCARDIOGRAPHY; ELECTROCARDIOGRAM; EXERCISE; GANGRENE; GASTROINTESTINAL HEMORRHAGE; GASTROINTESTINAL OBSTRUCTION; GRAFT VERSUS HOST REACTION; HEART ARRHYTHMIA; HEART BLOCK; HEART FAILURE; HEART MUSCLE FIBROSIS; HEART MUSCLE ISCHEMIA; HEART RIGHT VENTRICLE FAILURE; HEART TAMPONADE; HEART VENTRICLE TACHYCARDIA; HEARTBURN; HEMODYNAMIC PARAMETERS; HEMOFILTRATION; HUMAN; INTENSIVE CARE; INTERSTITIAL LUNG DISEASE; INTESTINE OBSTRUCTION; LIMB ISCHEMIA; LUNG ARTERY PRESSURE; LUNG FIBROSIS; LUNG TRANSPLANTATION; MALABSORPTION; MORPHEA; NUTRITIONAL SUPPORT; PERICARDIAL DISEASE; PERICARDIAL EFFUSION; PRIORITY JOURNAL; PULMONARY HYPERTENSION; PULMONARY VENO-OCCLUSIVE DISEASE; RESPIRATORY FAILURE; REVIEW; SCLERODERMA; SKIN FIBROSIS; STOMACH ANTRUM VASCULAR ECTASIA; SUDDEN DEATH; SUPRAVENTRICULAR TACHYCARDIA; SYNDROME CREST; SYSTEMIC LUPUS ERYTHEMATOSUS; SYSTEMIC SCLEROSIS; TOTAL PARENTERAL NUTRITION; VASCULAR DISEASE;

GASTROINTESTINAL DISEASES; HEART DISEASES; HUMANS; HYPERTENSION, PULMONARY; INTENSIVE CARE; LUNG DISEASES; PERICARDIUM; RAYNAUD DISEASE; RENAL INSUFFICIENCY; SCLERODERMA, SYSTEMIC; VASCULAR DISEASES;

EID: 77956274882     PISSN: 08850666     EISSN: 15251489     Source Type: Journal    
DOI: 10.1177/0885066610371181     Document Type: Review

References (105)

1. Steen VD, Medsger TA Jr. Severe organ involvement in systemic sclerosis with diffuse scleroderma. Arthritis Rheum. 2000 ; 43 (11). 2437-2444.
2. Steen VD, Follansbee WP, Conte CG, Medsger TA Jr. Thallium perfusion defects predict subsequent cardiac dysfunction in patients with systemic sclerosis. Arthritis Rheum. 1996 ; 39 (4). 677-681.
3. Follansbee WP, Curtiss EI, Rahko PS, et al. The electrocardiogram in systemic sclerosis (scleroderma). Study of 102 consecutive cases with functional correlations and review of the literature. Am J Med. 1985 ; 79 (2). 183-192.
4. Fernandes F., Ramires FJ, Arteaga E., Ianni BM, Bonfa ES, Mady C. Cardiac remodeling in patients with systemic sclerosis with no signs or symptoms of heart failure: an endomyocardial biopsy study. J Card Fail. 2003 ; 9 (4). 311-317.
5. Lekakis J., Mavrikakis M., Emmanuel M., et al. Cold-induced coronary Raynaud's phenomenon in patients with systemic sclerosis. Clin Exp Rheumatol. 1998 ; 16 (2). 135-140.
6. Coghlan JG, Mukerjee D. The heart and pulmonary vasculature in scleroderma: clinical features and pathobiology. Curr Opin Rheumatol. 2001 ; 13 (6). 495-499.
7. Vignaux O., Allanore Y., Meune C., et al. Evaluation of the effect of nifedipine upon myocardial perfusion and contractility using cardiac magnetic resonance imaging and tissue Doppler echocardiography in systemic sclerosis. Ann Rheum Dis. 2005 ; 64 (9). 1268-1273.
8. Kostis JB, Seibold JR, Turkevich D., et al. Prognostic importance of cardiac arrhythmias in systemic sclerosis. Am J Med. 1988 ; 84 (6). 1007-1015.
9. Williams MH, Handler CE, Akram R., et al. Role of N-terminal brain natriuretic peptide (N-TproBNP) in scleroderma-associated pulmonary arterial hypertension. Eur Heart J. 2006 ; 27 (12). 1485-1494.
10. Steiner JA, Cooper R., Gear JS, Ledingham JG Vascular symptoms in patients with primary Raynaud's phenomenon are not exacerbated by propranolol or labetalol. Br J Clin Pharmacol. 1979 ; 7 (4). 401-403.
11. Byers RJ, Marshall DA, Freemont AJ Pericardial involvement in systemic sclerosis. Ann Rheum Dis. 1997 ; 56 (6). 393-394.
12. D'Alonzo GE, Barst RJ, Ayres SM, et al. Survival in patients with primary pulmonary hypertension. Results from a national prospective registry. Ann Intern Med. 1991 ; 115 (5). 343-349.
13. Gaine SP, Rubin LJ Primary pulmonary hypertension. Lancet. 1998 ; 352 (9129). 719-725.
14. Rich S., Dantzker DR, Ayres SM, et al. Primary pulmonary hypertension. A national prospective study. Ann Intern Med. 1987 ; 107 (2). 216-223.
15. Simonneau G., Galie N., Rubin LJ, et al. Clinical classification of pulmonary hypertension. J Am Coll Cardiol. 2004 ; 43 (12 suppl S). 5S - 12S.
16. Chin KM, Kim NH, Rubin LJ The right ventricle in pulmonary hypertension. Coron Artery Dis. 2005 ; 16 (1). 13-18.
17. Budhiraja R., Tuder RM, Hassoun PM Endothelial dysfunction in pulmonary hypertension. Circulation. 2004 ; 109 (2). 159-165.
18. Humbert M., Sitbon O., Simonneau G. Treatment of pulmonary arterial hypertension. N Engl J Med. 2004 ; 351 (14). 1425-1436.
19. Kawut SM, Taichman DB, Archer-Chicko CL, Palevsky HI, Kimmel SE Hemodynamics and survival in patients with pulmonary arterial hypertension related to systemic sclerosis. Chest. 2003 ; 123 (2). 344-350.
20. Fisher MR, Mathai SC, Champion HC, et al. Clinical differences between idiopathic and scleroderma-related pulmonary hypertension. Arthritis Rheum. 2006 ; 54 (9). 3043-3050.
21. MacGregor AJ, Canavan R., Knight C., et al. Pulmonary hypertension in systemic sclerosis: risk factors for progression and consequences for survival. Rheumatology (Oxford). 2001 ; 40 (4). 453-459.
22. Deng Z., Morse JH, Slager SL, et al. Familial primary pulmonary hypertension (gene PPH1) is caused by mutations in the bone morphogenetic protein receptor-II gene. Am J Hum Genet. 2000 ; 67 (3). 737-744.
23. Lane KB, Machado RD, Pauciulo MW, et al. Heterozygous germ-line mutations in BMPR2, encoding a TGF-beta receptor, cause familial primary pulmonary hypertension. The International PPH Consortium. Nat Genet. 2000 ; 26 (1). 81-84.
24. Murata I., Kihara H., Shinohara S., Ito K. Echocardiographic evaluation of pulmonary arterial hypertension in patients with progressive systemic sclerosis and related syndromes. Jpn Circ J. 1992 ; 56 (10). 983-991.
25. Battle RW, Davitt MA, Cooper SM, et al. Prevalence of pulmonary hypertension in limited and diffuse scleroderma. Chest. 1996 ; 110 (6). 1515-1519.
26. Stupi AM, Steen VD, Owens GR, Barnes EL, Rodnan GP, Medsger TA Jr. Pulmonary hypertension in the CREST syndrome variant of systemic sclerosis. Arthritis Rheum. 1986 ; 29 (4). 515-524.
27. Hachulla E., Gressin V., Guillevin L., et al. Early detection of pulmonary arterial hypertension in systemic sclerosis: a French nationwide prospective multicenter study. Arthritis Rheum. 2005 ; 52 (12). 3792-3800.
28. Mukerjee D., St George D., Coleiro B., et al. Prevalence and outcome in systemic sclerosis associated pulmonary arterial hypertension: application of a registry approach. Ann Rheum Dis. 2003 ; 62 (11). 1088-1093.
29. Mayes MD Scleroderma epidemiology. Rheum Dis Clin North Am. 2003 ; 29 (2). 239-254.
30. Steen VD, Medsger TA Changes in causes of death in systemic sclerosis, 1972-2002. Ann Rheum Dis. 2007 ; 66 (7). 940-944.
31. Giaid A., Saleh D. Reduced expression of endothelial nitric oxide synthase in the lungs of patients with pulmonary hypertension. N Engl J Med. 1995 ; 333 (4). 214-221.
32. Tuder RM, Cool CD, Geraci MW, et al. Prostacyclin synthase expression is decreased in lungs from patients with severe pulmonary hypertension. Am J Respir Crit Care Med. 1999 ; 159 (6). 1925-1932.
33. Giaid A., Yanagisawa M., Langleben D., et al. Expression of endothelin-1 in the lungs of patients with pulmonary hypertension. N Engl J Med. 1993 ; 328 (24). 1732-1739.
34. Sanchez O., Sitbon O., Jais X., Simonneau G., Humbert M. Immunosuppressive therapy in connective tissue diseases-associated pulmonary arterial hypertension. Chest. 2006 ; 130 (1). 182-189.
35. Vane JR, Anggard EE, Botting RM Regulatory functions of the vascular endothelium. N Engl J Med. 1990 ; 323 (1). 27-36.
36. Barst RJ, Rubin LJ, Long WA, et al. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. N Engl J Med. 1996 ; 334 (5). 296-301.
37. McLaughlin VV, Genthner DE, Panella MM, Rich S. Reduction in pulmonary vascular resistance with long-term epoprostenol (prostacyclin) therapy in primary pulmonary hypertension. N Engl J Med. 1998 ; 338 (5). 273-277.
38. Rubin LJ, Mendoza J., Hood M., et al. Treatment of primary pulmonary hypertension with continuous intravenous prostacyclin (epoprostenol): results of a randomized trial. Ann Intern Med. 1990 ; 112 (7). 485-491.
39. McLaughlin VV, Shillington A., Rich S. Survival in primary pulmonary hypertension: the impact of epoprostenol therapy. Circulation. 2002 ; 106 (12). 1477-1482.
40. Sitbon O., Humbert M., Nunes H., et al. Long-term intravenous epoprostenol infusion in primary pulmonary hypertension: prognostic factors and survival. J Am Coll Cardiol. 2002 ; 40 (4). 780-788.
41. Badesch DB, Tapson VF, McGoon MD, et al. Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease. A randomized, controlled trial. Ann Intern Med. 2000 ; 132 (6). 425-434.
42. Farber HW, Graven KK, Kokolski G., Korn JH Pulmonary edema during acute infusion of epoprostenol in a patient with pulmonary hypertension and limited scleroderma. J Rheumatol. 1999 ; 26 (5). 1195-1196.
43. Palmer SM, Robinson LJ, Wang A., Gossage JR, Bashore T., Tapson VF Massive pulmonary edema and death after prostacyclin infusion in a patient with pulmonary veno-occlusive disease. Chest. 1998 ; 113 (1). 237-240.
44. Dorfmuller P., Humbert M., Perros F., et al. Fibrous remodeling of the pulmonary venous system in pulmonary arterial hypertension associated with connective tissue diseases. Hum Pathol. 2007 ; 38 (6). 893-902.
45. Simonneau G., Barst RJ, Galie N., et al. Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: a double-blind, randomized, placebo-controlled trial. Am J Respir Crit Care Med. 2002 ; 165 (6). 800-804.
46. Tapson VF, Gomberg-Maitland M., McLaughlin VV, et al. Safety and efficacy of IV treprostinil for pulmonary arterial hypertension: a prospective, multicenter, open-label, 12-week trial. Chest. 2006 ; 129 (3). 683-688.
47. Oudiz RJ, Farber HW Dosing considerations in the use of intravenous prostanoids in pulmonary arterial hypertension: an experience-based review. Am Heart J. 2009 ; 157 (4). 625-635.
48. Kallen AJ, Lederman E., Balaji A., et al. Bloodstream infections in patients given treatment with intravenous prostanoids. Infect Control Hosp Epidemiol. 2008 ; 29 (4). 342-349.
49. Rubin LJ, Badesch DB, Barst RJ, et al. Bosentan therapy for pulmonary arterial hypertension[see comment] [erratum appears in N Engl J Med 2002 Apr 18;346(16):1258]. N Engl J Med. 2002 ; 346 (12). 896-903.
50. Channick RN, Simonneau G., Sitbon O., et al. Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled study. Lancet. 2001 ; 358 (9288). 1119-1123.
51. Galie N., Olschewski H., Oudiz RJ, et al. Ambrisentan for the treatment of pulmonary arterial hypertension: results of the ambrisentan in pulmonary arterial hypertension, randomized, double-blind, placebo-controlled, multicenter, efficacy (ARIES) study 1 and 2. Circulation. 2008 ; 117 (23). 3010-3019.
52. Denton CP, Humbert M., Rubin L., Black CM Bosentan treatment for pulmonary arterial hypertension related to connective tissue disease: a subgroup analysis of the pivotal clinical trials and their open-label extensions. Ann Rheum Dis. 2006 ; 65 (10). 1336-1340.
53. Galie N., Ghofrani HA, Torbicki A., et al. Sildenafil citrate therapy for pulmonary arterial hypertension. N Engl J Med. 2005 ; 353 (20). 2148-2157.
54. Badesch DB, Hill NS, Burgess G., et al. Sildenafil for pulmonary arterial hypertension associated with connective tissue disease. J Rheumatol. 2007 ; 34 (12). 2417-2422.
55. McLaughlin VV, Oudiz RJ, Frost A., et al. Randomized study of adding inhaled iloprost to existing bosentan in pulmonary arterial hypertension. Am J Respir Crit Care Med. 2006 ; 174 (11). 1257-1263.
56. Hoeper MM, Leuchte H., Halank M., et al. Combining inhaled iloprost with bosentan in patients with idiopathic pulmonary arterial hypertension. Eur Respir J. 2006 ; 28 (4). 691-694.
57. Simonneau G., Rubin LJ, Galie N., et al. Addition of sildenafil to long-term intravenous epoprostenol therapy in patients with pulmonary arterial hypertension: a randomized trial. Ann Intern Med. 2008 ; 149 (8). 521-530.
58. Mathai SC, Girgis RE, Fisher MR, et al. Addition of sildenafil to bosentan monotherapy in pulmonary arterial hypertension. Eur Respir J. 2007 ; 29 (3). 469-475.
59. Pietra GG, Edwards WD, Kay JM, et al. Histopathology of primary pulmonary hypertension. A qualitative and quantitative study of pulmonary blood vessels from 58 patients in the National Heart, Lung, and Blood Institute, Primary Pulmonary Hypertension Registry. Circulation. 1989 ; 80 (5). 1198-1206.
60. Fuster V., Steele PM, Edwards WD, Gersh BJ, McGoon MD, Frye RL Primary pulmonary hypertension: natural history and the importance of thrombosis. Circulation. 1984 ; 70 (4). 580-587.
61. Rich S., Kaufmann E., Levy PS The effect of high doses of calcium-channel blockers on survival in primary pulmonary hypertension. N Engl J Med. 1992 ; 327 (2). 76-81.
62. Berezne A., Valeyre D., Ranque B., Guillevin L., Mouthon L. Interstitial lung disease associated with systemic sclerosis: what is the evidence for efficacy of cyclophosphamide ? Ann N Y Acad Sci. 2007 ; 1110: 271-284.
63. van Laar JM, Stolk J., Tyndall A. Scleroderma lung: pathogenesis, evaluation and current therapy. Drugs. 2007 ; 67 (7). 985-996.
64. Strange C., Highland KB Interstitial lung disease in the patient who has connective tissue disease. Clin Chest Med. 2004 ; 25 (3). 549-559, vii.
65. White B. Interstitial lung disease in scleroderma. Rheum Dis Clin North Am. 2003 ; 29 (2). 371-390.
66. Latsi PI, Wells AU Evaluation and management of alveolitis and interstitial lung disease in scleroderma. Curr Opin Rheumatol. 2003 ; 15 (6). 748-755.
67. Nannini C., West CP, Erwin PJ, Matteson EL Effects of cyclophosphamide on pulmonary function in patients with scleroderma and interstitial lung disease: a systematic review and meta-analysis of randomized controlled trials and observational prospective cohort studies. Arthritis Res Ther. 2008 ; 10 (5). R124.
68. Tashkin DP, Elashoff R., Clements PJ, et al. Cyclophosphamide versus placebo in scleroderma lung disease. N Engl J Med. 2006 ; 354 (25). 2655-2666.
69. Schachna L., Medsger TA Jr, Dauber JH, et al. Lung transplantation in scleroderma compared with idiopathic pulmonary fibrosis and idiopathic pulmonary arterial hypertension. Arthritis Rheum. 2006 ; 54 (12). 3954-3961.
70. Simms RW, Korn JH Systemic sclerosis: the spectrum, immunopathogenesis, clinical features, and treatment. In: Adu D, Emery P, Madaio M, eds. Rheumatology and the kidney. Oxford: Oxford University Press; 2001: 275-293.
71. Steen V., Steen V. Scleroderma renal crisis.[comment]. Indian J Med Sci. 2007 ; 61 (2). 71-72.
72. Steen VD Renal involvement in systemic sclerosis. [Review] [26 refs]. Clin Dermatol. 1994 ; 12 (2). 253-258.
73. Steen VD Scleroderma renal crisis. Rheum Dis Clin North Am. 1996 ; 22 (4). 861-878.
74. Steen VD, Mayes MD, Merkel PA Assessment of kidney involvement. Clin Exp Rheumatol. 2003 ; 21 (suppl 29). S29 - S31.
75. Traub YM, Shapiro AP, Rodnan GP, et al. Hypertension and renal failure (scleroderma renal crisis) in progressive systemic sclerosis. Review of a 25-year experience with 68 cases. Medicine. 1983 ; 62 (6). 335-352.
76. Thurm CA, Wigley FM, Dole WP, Wise RA Failure of vasodilator infusion to alter pulmonary diffusing capacity in systemic sclerosis. Am J Med. 1991 ; 90: 547-552.
77. Wigley FM, Flavahan N. Raynaud's phenomenon. Rheum Dis Clin North Am. 1996 ; 22: 4 ; 765-781.
78. Hummers LK, Wigley FM, Hummers LK, Wigley FM Management of Raynaud's phenomenon and digital ischemic lesions in scleroderma. Rheum Dis Clin North Am. 2003 ; 29 (2). 293-313.
79. Barr WG, Fahey PJ Reduction of pulmonary capillary blood volume following cold exposure in patients with Raynaud's phenomenon. Chest. 1988 ; 94 (6). 1195-1199.
80. Biondi ML, Marasini B., Bassani C., Agostoni A. Increased plasma endothelin levels in patients with Raynaud's phenomenon. N Engl J Med. 1991 ; 324 (16). 1139-1140.
81. Brain SD, Crossman DC, Buckley TL, Williams TJ Endothelin-1: demonstration of potent effects on the microcirculation of humans and other species. J Cardiovasc Pharmacol. 1989 ; 13 (suppl 5). S147 - S150.
82. Cimminiello C., Milani M., Uberti T., Arpaia G., Perolini S., Bonfardeci G. Endothelin, vasoconstriction, and endothelial damage in Raynaud's phenomenon. Lancet. 1991 ; 337 (8733). 114-115.
83. Freedman RR, Sabharwal SC, Desai N., Wenig P., Mayes M. Increased a-adrenergic responsiveness in idiopathic Raynaud's disease. Arthritis Rheum. 1989 ; 32 (1). 61-65.
84. Graafsma SJ, Wollersheim H., Droste HT, et al. Adrenoceptors on blood cells from patients with primary Raynaud's phenomenon. Clin Sci. 1991 ; 80 (4). 325-331.
85. Guimaraes S., Moura D. Vascular adrenoceptors: an update.[erratum appears in Pharmacol Rev 2001 Sep; 53 (3). 451 ]. Pharmacol Rev. 2001 ; 53 (2). 319-356.
86. Kanno K., Hirata Y., Emori T., et al. Endothelin and Raynaud's phenomenon. Am J Med. 1991 ; 90 (1). 130-132.
87. Kiowski W., Lüscher TF, Linder L., Bühler FR Endothelin-1-induced vasoconstriction in humans: reversal by calcium channel blockade but not by nitrovasodilators or endothelium-derived relaxing factor. Circulation. 1991 ; 83 (2). 469-475.
88. Smyth AE, Bell AL, Bruce IN, McGrann S., Allen JA Digital vascular responses and serum endothelin-1 concentrations in primary and secondary Raynaud's phenomenon. Ann Rheum Dis. 2000 ; 59 (11). 870-874.
89. Minchenko A., Bauer T., Salceda S., Caro J. Hypoxic stimulation of vascular endothelial growth factor expression in vitro and in vivo. Lab Invest. 1994 ; 71 (3). 374-379.
90. Mittag M., Beckheinrich P., Haustein UF Systemic sclerosis-related Raynaud's phenomenon: effects of iloprost infusion therapy on serum cytokine, growth factor and soluble adhesion molecule levels. Acta Derm Venereol. 2001 ; 81 (4). 294-297.
91. Distler JH, Kalden JR, Gray S., Distler O. [Vascular changes in the pathogenesis of systemic sclerosis]. Z Rheumatol. 2004 ; 63 (6). 446-450.
92. Hachulla E., Clerson P., Launay D., et al. Natural history of ischemic digital ulcers in systemic sclerosis: single-center retrospective longitudinal study. J Rheumatol. 2007 ; 34 (12). 2423-2430.
93. Ostojic P., Damjanov N., Pavlov-Dolijanovic S., et al. Peripheral vasculopathy in patients with systemic sclerosis: difference in limited and diffuse subset of disease. Clin Hemorheol Microcirc. 2004 ; 31 (4). 281-285.
94. Moore SC, Desantis ER, Moore SC, Desantis ERH. Treatment of complications associated with systemic sclerosis. Am J Health Syst Pharm. 2008 ; 65 (4). 315-321.
95. Varga J. New hope for systemic sclerosis patients with digital ulcers. Curr Rheumatol Rep. 2005 ; 7 (2). 127-128.
96. Zachariae H., Halkier-Sorensen L., Bjerring P., Heickendorff L. Treatment of ischaemic digital ulcers and prevention of gangrene with intravenous iloprost in systemic sclerosis. Acta Derm Venereol. 1996 ; 76 (3). 236-238.
97. Bluestone R., Macmahon M., Dawson JM Systemic sclerosis and small bowel involvement. Gut. 1969 ; 10 (3). 185-193.
98. Kaye SA, Seifalian AM, Lim SG, Hamilton G., Black CM Ischaemia of the small intestine in patients with systemic sclerosis: Raynaud's phenomenon or chronic vasculopathy ? QJM. 1994 ; 87 (8). 495-500.
99. Kaye SA, Lim SG, Taylor M., Patel S., Gillespie S., Black CM Small bowel bacterial overgrowth in systemic sclerosis: detection using direct and indirect methods and treatment outcome. Br J Rheumatol. 1995 ; 34 (3). 265-269.
100. Sjogren RW Gastrointestinal motility disorders in scleroderma. Arthritis Rheum. 1994 ; 37 (9). 1265-1282.
101. Bloch F., Leport J., Mallet L., Fiessinger JN, Housset E., Petite JP [Spontaneous pneumoperitoneum in scleroderma]. Gastroenterol Clin Biol. 1984 ; 8 (6-7). 557-559.
102. Ebert EC, Ruggiero FM, Seibold JR Intestinal perforation. A common complication of scleroderma. Dig Dis Sci. 1997 ; 42 (3). 549-553.
103. Watson M., Hally RJ, McCue PA, Varga J., Jimenez SA Gastric antral vascular ectasia (watermelon stomach) in patients with systemic sclerosis. Arthritis Rheumat. 1996 ; 39 (2). 341-346.
104. Calamia KT, Scolapio JS, Viggiano TR. Endoscopic YAG laser treatment of watermelon stomach (gastric antral vascular ectasia) in patients with systemic sclerosis. Clinical Exp Rheumatol. 2000 ; 18 (5). 605-608.
105. Shalev T., Haviv Y., Segal E., et al. Outcome of patients with scleroderma admitted to intensive care unit. A report of nine cases. Clin Exp Rheumatol. 2006 ; 24 (4). 380-386.